Efficacy and cost-effectiveness analysis of moxifloxacin hydrochloride and combination of ceftriaxone sodium with azithromycin in the treatment of moderate to severe community acquired pneumonia in elderly patients

Objective:To evaluate the clinical consequences and cost-effectiveness of moxifloxacin hydrochloride and combination of ceftriaxone sodium with azithromycin in the treatment of moderate to severe community acquired pneumonia in elderly patients. Methods:A total of 100 elderly patients with moderate to severe community acquired pneumonia in our hospital were randomly divided into moxifloxacin hydrochloride group (n=50) and combination of ceftriaxone sodium with azithromycin group (n=50). The therapeutic effects were monitored and the cost-effectiveness analysis was conducted on the two groups. Results:The total costs of the moxifloxacin group and the combination group were 2 305.52 Yuan and 2 477.79 Yuan; the total effective rates were 90.00% and 84.00%(P0.05); the cost-effectiveness ratios were 25.62 and 29.50; the incidence of adverse drug reactions were 8.00% and 10.00%(P0.05),respectively. Conclusion:Moxifloxacin hydrochloride is a better option in the treatment of moderate to severe community acquired pneumonia in elderly patients.